Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis

ZENGYUN LI¹, PEILIANG ZHANG², QINGTONG MA¹, DONGQING WANG³ and TAO ZHOU³

¹Department of Oncology, Laiwu Municipal Hospital of Traditional Chinese Medicine, Laiwu, Shandong 271100; ²Department of Radiation Oncology, Yishui Central Hospital, Yishui, Shandong 276400; ³Department of Radiation Oncology, Shandong Tumor Hospital, Jinan, Shandong 250117, P.R. China

Received March 10, 2016; Accepted October 20, 2016

DOI: 10.3892/mco.2017.1222

Abstract. Treatment with 5-fluorouracil (5-FU) and cisplatin (PF regimen) remains the most frequently used chemotherapy for esophageal squamous cell carcinoma (SCC). The aim of the present study was to assess the efficacy and safety of pemetrexed/cisplatin (PP regimen) as definitive treatment compared with PF. A total of 60 patients with locally advanced, unresectable SCC of the esophagus receiving concomitant chemoradiotherapy were recruited in this study; of those patients, 29 received four cycles (two concomitant and two post-radiotherapy) of the PF regimen (arm A, cisplatin 25 mg/m²/day i.v. on days 1-3 plus 5-FU 800 mg/m²/24 h by continuous infusion on days 1-5) and 31 received four cycles of the PP regimen (arm B, cisplatin 25 mg/m²/day i.v. on days 1-3 plus pemetrexed 500 mg/m² on day 1). All the patients in both arms received a total radiation dose of 59.6 Gy. The two arms were well-matched for age, gender, Karnofsky performance status, TNM stage, tumor location and length. The overall response rate was 89.7% in arm A vs. 93.5% in arm B (P>0.05). The median overall survival was 26.1 months [95% confidence interval (CI): 15.3-36.8 months] in arm A vs. 28.7 months (95% CI: 9.4-48.0 months) in arm B (P=0.05). Severe esophagitis occurred in 31.0% (9/29) of the patients in arm A vs. 12.9% (4/31) of the patients in arm B; the difference was statistically significant (P=0.036). Grade 3/4 leukopenia and thrombocytopenia occurred in 4 (13.8%) and 1 (3.4%) patients, respectively, in arm A vs. 12 (38.7%) and 6 (19.4%) patients, respectively, in arm B; the differences were statistically significant (P=0.029 and 0.041, respectively). Therefore, chemoradiotherapy with the PP regimen achieved therapeutic results comparable with those of the PF regimen; in terms of toxicity, the incidence of hematological toxicity was higher and that of esophagitis was lower with the PP regimen.

Introduction

Concurrent chemoradiotherapy has been established as one of the standard therapies for patients with locally advanced, unresectable esophageal carcinoma based on the results of the Radiation Therapy Oncology Group (RTOG) 85-01 and 95-04 trials, which demonstrated a significant survival advantage of concurrent chemoradiation over radiation alone (1,2). However, a standard and effective chemotherapeutic regimen for combining with radiotherapy has not yet been established.

Although the standard chemotherapeutic agents for esophageal carcinoma have not yet been determined, various types of chemotherapy regimens have been investigated in an attempt to prolong survival and improve quality of life. The most frequently used chemotherapeutic agents in esophageal cancer treatment are combined cisplatin and 5-fluorouracil (5-FU) (1-3). A phase II study (3) by the Japan Clinical Oncology Group reported that the complete response rate with cisplatin/5-FU (PF regimen) and radiotherapy for stage II-III esophageal squamous cell carcinoma (SCC) achieved a response rate of 62.2% (46/74); the median survival time was 29 months, with 3- and 5-year survival rates of 44.7 and 36.8%, respectively. However, half the cases in these series of patients included potentially resectable carcinomas. A better prognosis with chemoradiotherapy in esophageal SCC was reported by Zhao et al (4), with a median survival time of 30.8 months and a 5-year survival rate of 40% for stage I-II patients treated with the PF regimen combined with late-course accelerated hyperfractionated radiotherapy (LCAHRT).

In order to increase the therapeutic ratio over that of standard PF-based chemoradiotherapy, attempts have been made in a phase I/II study to incorporate next-generation cytotoxic chemotherapeutic agents, such as docetaxel (5,6). However, survival remains disappointing and did not improve with the standard PF regimen. Treatment-related toxicities may compromise clinical efficacy (6). Therefore, new drugs and combinations with a better therapeutic index are required.
More recently, pemetrexed was introduced in phase I trials for esophageal SCC and the preliminary results are promising (7). As a novel antimitabolite, pemetrexed acts as a multitargeted antifolate by inhibiting several key enzymes involved in nucleotide synthesis (8). Pemetrexed, as a single agent or combined with platinum, has also demonstrated broad antitumor activity in a wide variety of solid tumors (9). In a phase I trial (7), pemetrexed was evaluated in combination with cisplatin and concurrent selective lymph node LCAHRT for patients with locally advanced esophageal SCC; that study demonstrated that the maximum tolerated dose of pemetrexed was 500 mg/m² and the recommended dose was 400 mg/m². Although toxicities were common, the protocol was overall safe, well-tolerated, and achieved an encouraging outcome.

One phase II study (10) investigated 500 mg/m² neoadjuvant pemetrexed and carboplatin in conjunction with concomitant radiation of 50.4 Gy followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. This phase II study reported a 23% (6/26) pathological complete response and 22 patients underwent complete cancer resection, with a median survival time of 17.8 months [95% confidence interval (CI): 12.2-30.7 months]. However, 22 patients had at least one grade ≥3 adverse event, and 3 deaths were reported postoperatively.

To the best of our knowledge, until recently there were no published studies focusing on the efficacy and safety of pemetrexed/cisplatin (PP regimen) compared with the PF regimen in concomitant chemoradiotherapy. Therefore, the objective of the present study was to evaluate the combination of pemetrexed and cisplatin in patients with locally advanced, unresectable esophageal SCC.

Patients and methods

Design. A retrospective study was conducted to determine the efficacy and safety of the PP vs. the PF regimen in patients with locally advanced, unresectable esophageal SCC treated with concomitant chemoradiotherapy. The primary objective was to assess tumor response and overall survival, and the secondary objective was to assess treatment-related toxicity. The Institutional Review Board of the Shandong Tumor Hospital (Jinan, China) approved the protocol of this retrospective study and all the patients provided written informed consent.

Patient population and eligibility. Between January, 2004 and November, 2011, 72 eligible patients underwent concomitant LCAHRT and cisplatin-based chemotherapy with a curative intent for the treatment of locally advanced, unresectable esophageal SCC at the Shandong Tumor Hospital. The eligibility criteria for this study were as follows: i) Karnofsky performance status score ≥70; ii) patients aged ≤75 years; iii) histologically confirmed SCC, previously untreated; and iv) clinical stage T1-T4, N0/1, M0/1a according to the American Joint Committee staging system (2002) (11). The exclusion criteria included distant organ metastases, evidence of esophageal perforation and other serious underlying medical conditions.

Treatment evaluation and details. The pretreatment evaluation generally included complete history and physical examination, complete blood cell count and serum chemistry profile, endoscopy with biopsy, upper gastrointestinal, chest and abdominal computed tomography (CT) scans and bone scan with single photon emission CT. In order to exclude patients with distant organ metastases, a magnetic resonance imaging scan of the brain and neck and a whole-body ¹⁸F-Fluorodeoxyglucose positron emission tomography scan were performed as part of routine evaluation.

The treatment scheme is summarized in Fig. 1. All the patients were scheduled to receive two cycles of concurrent cisplatin-based chemotherapy and radiation [LCAHRT; 59.6 Gy/34 fractions (fx)], followed by an additional two cycles of consolidation chemotherapy.

Chemotherapy. Patients in arm A were treated with the PF regimen (intravenous infusion of cisplatin 25 mg/m²/day on days 1-3 and continuous intravenous infusion of 5-fluorouracil 800 mg/m²/24 h on days 1-5, every 21 days). Patients in arm B were treated with the PP regimen (intravenous infusion of cisplatin 25 mg/m²/day on days 1-3 and pemetrexed 500 mg/m² on day 1, every 21 days). All the patients treated with the PP regimen received folic acid, vitamin B12 and steroid prophylaxis. Appropriate antiemetics were prescribed, and human granulocyte colony-stimulating factor was permitted during treatment.

Radiotherapy. The radiation dose was the same in both arms. The radiation was delivered by 6-MV X-rays using a two-course irradiation schedule: The first course of radiation covered the primary tumors, metastatic regional lymph node(s) and high-risk nodal regions (7,12), administered at 2 Gy per fx, 5 fx/week, to a total dose of 40 Gy in 20 fx; the second course of radiation was delivered to the boost volume for an additional dose of 19.6 Gy twice a day in 14 fx within 7 days at 1.4 Gy/fx, with a 6-h minimal interval between fractions. The total dose administered to the clinical tumor was 59.6 Gy/34 fx/35 days.

Treatment assessments. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (13). The response criteria for the target lesions are as follows: Complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease; stable disease (SD), neither PR nor PD criteria met; and progressive disease (PD), ≥20% increase or appearance of new lesion(s). The overall survival was calculated from the date of radiotherapy initiation until death or the last follow-up evaluation.

Treatment-related toxicity and follow-up. Treatment-related toxicity assessment was performed at least weekly during treatment, 4 weeks after completion of therapy, every 3 months for 2 years and every 6 months thereafter, using the National Cancer Institute Common Toxicity Criteria, version 3.0 (14). A full history and physical examination, as well as repeat blood work, were conducted at these visits. Spiral CT scans of the chest and upper gastrointestinal tract were obtained at every follow-up examination to evaluate the status of the disease.

Statistical analysis. The statistical analysis was performed using SPSS software, version 10.0 (SPSS Inc., Chicago, IL, USA). The survival analysis was performed using the
Results

Patient characteristics. Between January, 2004 and November, 2011, 29 patients were treated with the PF regimen (arm A) and 31 patients with the PP regimen (arm B). All the patients completed the treatment schedules and were assessable for treatment efficacy and toxicity.

The two arms were similar for baseline characteristics (Table I). Although more patients with early-stage disease (IIa+IIb) were included in arm B (29.0%) compared with arm A (13.8%), the difference was not statistically significant (P=0.266). The majority of the patients had stage III and IVa disease located in the thoracic esophagus.

Treatment response. According to RECIST, a response was reported in 26 of the 29 patients (89.7%) in arm A and in 29 of the 31 patients (93.5%) in arm B (Table II). The difference was not statistically significant (P=0.304).

Survival. The median follow-up was 25.1 months in both arms. The median survival time was 26.1 months (95% CI: 15.3-36.8 months) in arm A and 28.7 months (95% CI: 9.4-48.0 months) in arm B. At 1, 3 and 5 years, the overall survival rate was 84.4, 42.2 and 33.2% in arm A, and 71.3, 51.9 and 40.9% in arm B. However, there were no significant difference between arm A and arm B in terms of long-term survival (Chi-squared=0.034, P=0.853) (Fig. 2).

Toxicity. As demonstrated in Table III, the most frequently reported severe (grade ≥3) adverse effects were hematological toxicity and esophagitis. Treatment-related severe leukopenia and thrombocytopenia occurred in 4 (13.8%) and 1 (3.4%) patients, respectively, in arm A, and 12 (38.7%) and 6 (19.4%) patients, respectively, in arm B; the differences were statistically significant (P=0.029 and 0.041, respectively). Severe anaemia was reported in 3.4% (1 patient developed grade 4 anaemia) of the patients in arm A, and 12.9% in arm B; however, the difference was not statistically significant (P=0.059). A total of 9 patients (31.0%) in arm A and 4 patients (12.9%) in arm
chemoradiotherapy. Although limited by the small number of patients, our data suggest that the administration of pemetrexed may be feasible and well-tolerated in combination with radiotherapy; furthermore, this PP-based chemoradiotherapy achieved a tumor response rate of 93.5%, with acceptable toxicity and only 2 possibly treatment-related deaths. The control arm with the PF regimen exhibited a mildly inferior response rate (89.7%), whereas there were 4 reported toxicity-related deaths. The present study demonstrated that the incidence of hematological toxicities was higher with the PP compared with the PF regimen, which should be taken into consideration. However, the incidence of esophagitis with the PP regimen was lower compared with that with the PF regimen. The median survival in the PF arm was 26.1 months (95% CI: 5.3-36.8 months) and was superior to those reported by the RTOG 85-01 and RTOG 94-05 trials (14.1 and 18.1 months, respectively) (1,2). With the PP regimen, the median survival in our trial was 28.7 months (95% CI: 9.4-48.0 months), which was considered to be satisfactory, as it was longer by 2.6 months compared with the PF regimen. Of note, this rather good median survival was obtained while M1a-stage patients were included in this study, contrary to the RTOG 94-05 study.

It is considered that this survival benefit may be acquired by using an accelerated radiation scheme. In China, Shi et al (15) initiated a study on LCAHRT for esophageal SCC treatment and yielded very encouraging results. Compared with conventional fractionation, the 5-year survival (34 vs. 15%) and local control (55 vs. 21%) rates were markedly improved with the LCAHRT regimen. Recently, three independent meta-analyses added to the evidence of LCAHRT being therapeutically beneficial for esophageal carcinoma (16-18). However, the optimal combination of chemotherapy regimens and accelerated radiation to maximize long-term survival remains to be determined. Zhao et al (4) reported the results of a phase III clinical trial on LCAHFR combined with PF, and the 1, 3 and 5-year survival rates were 67, 44 and 40%, respectively, in the combination group, and 77, 39 and 28%, respectively, in the radiotherapy alone group (P=0.310); in addition, the incidence of grade ≥3 toxicities were 42 and 25%, respectively (P=0.05). Liu et al (17) reported a meta-analysis on LCAHRT in esophageal carcinoma, including 21 randomized controlled trials, and the results indicated that LCAHRT combined with the PF regimen may improve the 5-year overall survival and 3-year local control in esophageal cancer compared with LCAHRT alone, with a significantly increased incidence of acute toxicities.

Pemetrexed was recently approved in combination with cisplatin as first-line treatment for advanced non-squamous-cell lung cancer and pleural mesothelioma. Pemetrexed combined with platinum compounds was also recommended for locally advanced head and neck SCC as an induction regimen (19,20). However, there are very few data in the literature focusing on the treatment of esophageal SCC. To date, only one phase I study by Li et al (7) was conducted to evaluate the efficacy and safety of pemetrexed combined with cisplatin for locally advanced esophageal SCC. That study included 12 patients with T3-4NO1M0-1a thoracic esophageal SCC. The total radiation dose administered was 59.6 Gy in 34 fx in 5.4 weeks, and concurrent chemotherapy regimens were prescribed with cisplatin 10 mg/m2 on days 1-5 and pemetrexed 400-500 mg/m2 once every 21 days. The tumor response was as high as 100%, with CR in 66.7% (8/12) and PR in
In the present study, although supportive treatment with oral folic acid and intramuscular vitamin B12 was routinely administered, the incidence of leukopenia and thrombocytopenia was higher with pemetrexed at a dose of 500 mg/m² on day 1 once every 21 days, compared with that with 5-FU (Table III). Generally, these toxicities were tolerable; in only 3 patients the consolidation chemotherapy was delayed due to grade 4 hematological toxicity (2 patients developed thrombocytopenia and 1 developed leukopenia), and only 2 deaths were considered possibly related to this treatment regimen (1 patient developed upper gastrointestinal hemorrhage and 1 patient developed esophagotracheal fistula). As regards overall survival, the present study demonstrated that the PP regimen was marginally superior to the PF regimen for locally advanced esophageal SCC (5-year survival rate, 40.9 vs. 33.2%, respectively), although more patients with early-stage disease (IIa+IIb) were included in the PP group compared with the PF group (29.0 vs. 13.8%, respectively). As demonstrated in Fig. 2, a trend toward better survival among patients who received the PP regimen was observed, but the difference did not reach statistical significance for this limited patient population.

Several strengths and limitations should be noted. This was only a retrospective study with a relatively small sample size, which may limit the generalizability of our findings. This study cohort consisted of an inhomogeneous patient population including patients with stage II, III and IVa disease, who had different prognoses following treatment. In conclusion, the present study demonstrated that chemoradiotherapy with pemetrexed/cisplatin was similar with cisplatin and 5-FU; however, the incidence of hematological toxicity was higher, whereas that of esophagitis was lower. These results should be validated in a large prospective cohort of patients.

References


